Literature DB >> 35663105

Rare Blood Cancers in 2021: Importance of Continued Exchange of Ideas.

Naveen Pemmaraju1.   

Abstract

Entities:  

Year:  2021        PMID： 35663105      PMCID： PMC9138440          DOI： 10.36401/JIPO-21-X6

Source DB:  PubMed          Journal:  J Immunother Precis Oncol        ISSN： 2590-017X


× No keyword cloud information.
  6 in total

1.  Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

Authors:  Naveen Pemmaraju; Andrew A Lane; Kendra L Sweet; Anthony S Stein; Sumithira Vasu; William Blum; David A Rizzieri; Eunice S Wang; Madeleine Duvic; J Mark Sloan; Sharon Spence; Shay Shemesh; Christopher L Brooks; John Balser; Ivan Bergstein; Jeffrey E Lancet; Hagop M Kantarjian; Marina Konopleva
Journal:  N Engl J Med       Date:  2019-04-25       Impact factor: 91.245

Review 2.  Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?

Authors:  Kevin Tang; Loretta J Nastoupil
Journal:  J Immunother Precis Oncol       Date:  2021-08-05

Review 3.  JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.

Authors:  Andrew T Kuykendall; Rami S Komrokji
Journal:  J Immunother Precis Oncol       Date:  2021-06-22

Review 4.  Chronic Myelomonocytic Leukemia: Hematopathology Perspective.

Authors:  Siba El Hussein; Sa A Wang; Naveen Pemmaraju; Joseph D Khoury; Sanam Loghavi
Journal:  J Immunother Precis Oncol       Date:  2021-06-18

Review 5.  Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.

Authors:  Sophia S Lee; Srdan Verstovsek; Naveen Pemmaraju
Journal:  J Immunother Precis Oncol       Date:  2021-06-29

Review 6.  Inflammation in Myeloid Malignancies: From Bench to Bedside.

Authors:  Eli M Soyfer; Angela G Fleischman
Journal:  J Immunother Precis Oncol       Date:  2021-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.